Table 3.
Disease activity assessments from sections A and B of the clinical vignettes
| Case number | Clinical symptoms | Acute-phase reactants | Section A: enrolled (n, %) | Section A: not enrolled (n, %) | FDG-PET | Section B: enrolled (n, %) | Section B: not enrolled (n, %) | Level of confidence (section A → B) |
|---|---|---|---|---|---|---|---|---|
| 1 | Active symptoms (carotidynia, headache) | Elevated | 54 (84) | 10 (16) | Active | 63 (98) | 1 (2) | 79% → 93% |
| 2 | Symptoms of damage (stable arm claudication) | Normal | 1 (2) | 61 (98) | Active | 20 (33) | 41 (67) | 74% → 69% |
| 3 | Symptoms of damage (stable arm claudication) | Normal | 0 (0) | 61 (100) | Inactive | 1 (2) | 60 (98) | 82% → 91% |
| 4 | Fatigue | Elevated | 19 (31) | 42 (69) | Active | 54 (89) | 7 (11) | 62% → 80% |
| 5 | Fatigue | Elevated | 16 (26) | 45 (74) | Inactive | 9 (15) | 52 (85) | 64% → 75% |
| 6 | Fatigue | Elevated | 24 (39) | 37 (61) | Active | 55 (90) | 6 (10) | 65% → 80% |
| 7 | No symptoms | Normal | 1 (2) | 60 (98) | Active | 21 (34) | 40 (66) | 83% → 69% |
| 8 | No symptoms | Normal | 2 (3) | 59 (97) | Inactive | 3 (5) | 58 (95) | 83% → 93% |
FDG-PET: 18F-fluorodeoxyglucose PET.